For instance, doxorubicin or PTX combination with PD-L1 (siRNA or antibody) showed excellent performances in synergistic chemoimmunotherapy through promoting tumor immunogenicity and blockading PD-1/PD-L1 axis [18, 19]. This evidence concerns the gene CD274 and neoplasm.